Osiris Therapeutics (OSIR) vs. SIGA Technologies (SIGA) Head-To-Head Survey

Osiris Therapeutics (OTCMKTS: OSIR) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Earnings & Valuation

This table compares Osiris Therapeutics and SIGA Technologies’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Osiris Therapeutics $59.87 million 3.45 -$1.78 million ($0.20) -29.95
SIGA Technologies $14.99 million 26.06 -$39.69 million ($0.49) -10.10

Osiris Therapeutics has higher revenue and earnings than SIGA Technologies. Osiris Therapeutics is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Osiris Therapeutics and SIGA Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Osiris Therapeutics 0 0 0 0 N/A
SIGA Technologies 0 0 0 0 N/A

Profitability

This table compares Osiris Therapeutics and SIGA Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Osiris Therapeutics N/A N/A N/A
SIGA Technologies -706.09% N/A -25.84%

Risk & Volatility

Osiris Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Institutional & Insider Ownership

0.3% of Osiris Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of SIGA Technologies shares are owned by institutional investors. 44.6% of Osiris Therapeutics shares are owned by insiders. Comparatively, 4.7% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Osiris Therapeutics beats SIGA Technologies on 7 of the 10 factors compared between the two stocks.

About Osiris Therapeutics

Osiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body’s natural healing. The Company’s products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company’s BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

About SIGA Technologies

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Receive News & Ratings for Osiris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply